Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab +/- Epacadostat vs EXTREME in 1L R/M HNSCC
NCT03358472Phase 3Completed
- Sponsor
- Incyte
- Start
- Dec 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of pembrolizumab, epacadostat in head and neck squamous cell carcinoma (HNSCC), sponsored by Incyte. Started Dec 2017; status: completed.
02
Drugs
pembrolizumabepacadostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03358472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358472.